Literature DB >> 10383501

The effect of Helicobacter pylori eradication on intragastric pH during dosing with lansoprazole or ranitidine.

M A van Herwaarden1, M Samsom, C H van Nispen, P G Mulder, A J Smout.   

Abstract

BACKGROUND: The antisecretory effect of omeprazole on intragastric pH is decreased in the absence of Helicobacter pylori. AIM: To investigate the effect of H. pylori eradication on intragastric pH during lansoprazole or ranitidine dosing in 41 asymptomatic H. pylori-positive subjects.
METHOD: Two groups of healthy H. pylori-positive volunteers were investigated. One group was dosed with lansoprazole 30 mg at 08.00 hours for at least 8 days, before and after 2 weeks of placebo-controlled double-blind eradication therapy using ranitidine bismuth citrate 400 mg b.d. and clarithromycin 500 mg b.d. The other group was dosed with ranitidine 300 mg at 23.00 hours for at least 8 days using the same trial design. An upper endoscopy was performed to establish H. pylori status by rapid urease test, culture and histology before both periods of dosing. Twenty-four hour intragastric pH recording was performed on the final day of all periods of dosing.
RESULTS: H. pylori eradication significantly decreased the intragastric pH reached during lansoprazole treatment throughout all periods of the day. Intragastric pH during ranitidine treatment was not affected by H. pylori eradication, except for the late-night period.
CONCLUSION: H. pylori eradication has a more pronounced effect on the acid-inhibiting properties of lansoprazole than on those of ranitidine.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10383501     DOI: 10.1046/j.1365-2036.1999.00531.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  10 in total

1.  Gastroesophageal reflux and Helicobacter pylori: a review.

Authors:  F Pace; G Bianchi Porro
Journal:  World J Gastroenterol       Date:  2000-06       Impact factor: 5.742

2.  Inhibitory potency of twice-a-day omeprazole on gastric acidity is enhanced by eradication of H. pylori in duodenal ulcer patients.

Authors:  A B R Thomson; M Keelan; R Lastiwka; S Appelman-Eszczuk; L Zuk; L Drozdowski; A Prentice; P Sinclair
Journal:  Dig Dis Sci       Date:  2003-10       Impact factor: 3.199

3.  Some Observations on PPI Therapy for Bleeding Ulcer.

Authors:  Grigoris I Leontiadis; Colin W Howden
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-08

Review 4.  Role of Helicobacter pylori eradication in aspirin or non-steroidal anti-inflammatory drug users.

Authors:  George-V Papatheodoridis; Athanasios-J Archimandritis
Journal:  World J Gastroenterol       Date:  2005-07-07       Impact factor: 5.742

Review 5.  Gastric acid inhibition in the treatment of peptic ulcer hemorrhage.

Authors:  Kevin A Ghassemi; Thomas O G Kovacs; Dennis M Jensen
Journal:  Curr Gastroenterol Rep       Date:  2009-12

6.  Comparing the acid-suppressive effects of three brands of generic lansoprazole with the original: pharmacokinetic bioequivalence tests do not necessarily guarantee pharmacodynamic equivalence.

Authors:  Tomohiko Shimatani; Seiko Hirokawa; Yumiko Tawara; Kazuko Hamai; Mutsuko Matsumoto; Susumu Tazuma; Masaki Inoue
Journal:  Dig Dis Sci       Date:  2008-12-18       Impact factor: 3.199

Review 7.  Intravenous pantoprazole as an adjuvant therapy following successful endoscopic treatment for peptic ulcer bleeding.

Authors:  Jun Wang; Kehu Yang; Bin Ma; Jinhui Tian; Yali Liu; Zhenggang Bai; Lei Jiang; Shaoliang Sun; Jun Li; Ruifeng Liu; Xiangyong Hao; Xiaodong He
Journal:  Can J Gastroenterol       Date:  2009-04       Impact factor: 3.522

Review 8.  The short-term medical management of non-variceal upper gastrointestinal bleeding.

Authors:  Thomas O G Kovacs; Dennis M Jensen
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 9.  Management of upper gastrointestinal bleeding.

Authors:  Thomas O G Kovacs
Journal:  Curr Gastroenterol Rep       Date:  2008-12

10.  Acid suppressant use in association with incidence and severe outcomes of COVID-19: a systematic review and meta-analysis.

Authors:  Hong-Bae Kim; Jung-Ha Kim; Bethany J Wolf
Journal:  Eur J Clin Pharmacol       Date:  2021-11-24       Impact factor: 3.064

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.